Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Avoidance of ATG improves outcomes in double-cord blood transplantation for hematological malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTao WangMHMeilun HeCBCara L. Benjamin

Discussion

Loading...

Member takes

Overview

Analysis shows avoidance of anti-thymocyte globulin improves survival and reduces complications in patients with hematological malignancies post double-cord blood transplantation.

Key Points

  • Overall survival and disease-free survival improved among patients avoiding anti-thymocyte globulin in double-cord blood transplantation.
  • Clinical outcomes were significantly better in terms of treatment-related mortality when ATG was not used during transplants.
  • Cox proportional hazards models were applied to assess the effects of guideline adherence on patient survival outcomes.
  • Adherence to guidelines enhances recovery from acute graft-versus-host disease and enhances clinical outcomes among hematological patients.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3e1https://doi.org/10.1182/blood-2025-2436
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single vs double cord blood transplantation: Improved engraftment with comparable efficacy2025
  2. 2CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia2025
  3. 3Single-unit cord blood transplantation reduces the risk of relapse and improves leukemia-free survival compared to other donor sources in allo-HSCT for patients with high-risk acute myeloid leukemia2025
  4. 4Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study2026
  5. 5Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025